Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | BLM | P54132 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380987 | 1.00 | CYP2D6 (0.30) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL27340865 | 1.00 | CYP2D6 (0.30) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL524795 | 1.00 | CYP2D6 (0.30) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL14829522 | 0.87 | CYP2C19 (0.41) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL14829268 | 0.87 | CYP2C19 (0.41) | CYP2D6LMNABLMALOX15TSHR | |
| SCHEMBL2154406 | 0.85 | ACE (0.36) | LMNACES2CES1 | |
| SCHEMBL11820398 | 0.85 | — | — | |
| SCHEMBL11819070 | 0.82 | — | — | |
| SCHEMBL3795815 | 0.82 | GABRR1 (0.30) | — | |
| SCHEMBL4029521 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335796-A1 | THIN-FILM COMPOSITE MEMBRANE AND METHODS OF MAKING AND USING THE SAME | THE PENN STATE RESEARCH FOUNDATION | 2024-10-10 | — | — | US | disclosed |
| US-12036515-B2 | Thin-film composite membrane and methods of making and using the same | THE PENN STATE RESEARCH FOUNDATION (PA) | 2024-07-16 | — | — | US | disclosed |
| US-20210370240-A1 | THIN-FILM COMPOSITE MEMBRANE AND METHODS OF MAKING AND USING THE SAME | THE PENN STATE RESEARCH FOUNDATION | 2021-12-02 | — | — | US | disclosed |
| EP-2788108-A1 | MEMBRANE, WATER TREATMENT SYSTEM, AND METHOD OF MAKING | General Electric Company (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-8591741-B2 | Thin film composite membranes incorporating carbon nanotubes | GENERAL ELECTRIC COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| WO-2013085657-A1 | MEMBRANE, WATER TREATMENT SYSTEM, AND METHOD OF MAKING | GENERAL ELECTRIC COMPANY (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130146530-A1 | MEMBRANE, WATER TREATMENT SYSTEM, AND METHOD OF MAKING | GENERAL ELECTRIC COMPANY (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120080381-A1 | THIN FILM COMPOSITE MEMBRANES INCORPORATING CARBON NANOTUBES | GENERAL ELECTRIC COMPANY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120080380-A1 | THIN FILM COMPOSITE MEMBRANES INCORPORATING CARBON NANOTUBES | GENERAL ELECTRIC COMPANY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | APPLIED NANOSYSTEMS B.V. (NL) | 2005-12-08 | — | — | US | disclosed |
| US-20050250857-A1 | Gelling agents | NANO FIBER MATRICES B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
| EP-1506168-A2 | GELLING AGENTS | Applied NanoSystems B.V. (NL) | 2005-02-16 | — | — | EP | disclosed |
| EP-1490028-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | Applied NanoSystems B.V. (NL) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003097587-A2 | GELLING AGENTS | APPLIED NANOSYSTEMS B.V. (NL) | 2003-11-27 | — | — | WO | disclosed |
| EP-1364941-A1 | Gelling agents | Applied NanoSystems B.V. (NL) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003084508-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | APPLIED NANOSYSTEMS B.V. (NL) | 2003-10-16 | — | — | WO | disclosed |
| US-5616249-A | USING ALL ALIPHATIC POLYAMIDES FROM POLYAMINO COMPOUNDS AND COMPOUNDS HAVING TWO OR MORE ACID HALIDE GROUPS | IONICS, INCORPORATED (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0587610-A1 | SPECIFICALLY BETA-BETA CROSS-LINKED HEMOGLOBINS AND METHOD OF PREPARATION | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1994-03-23 | — | — | EP | disclosed |
| US-5250665-A | Artificial blood | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | TACR1, TACR2, NPSR1 | CYP2D6 472/4885LMNA 238/4885BLM 4382/4885 |
| US-20240335796-A1 | THIN-FILM COMPOSITE MEMBRANE AND METHODS OF MAKING AND USING THE SAME | PORCN, MLEC, FLOT1 | CYP2D6 3627/4885LMNA 356/4885BLM 654/4885 |
| US-12036515-B2 | Thin-film composite membrane and methods of making and using the same | PORCN, MLEC, FLOT1 | CYP2D6 3627/4885LMNA 356/4885BLM 654/4885 |
| US-20210370240-A1 | THIN-FILM COMPOSITE MEMBRANE AND METHODS OF MAKING AND USING THE SAME | PORCN, MLEC, FLOT1 | CYP2D6 3627/4885LMNA 356/4885BLM 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.